1. Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies
- Author
-
Anne Cecile Zoung-Kany Bisseck, Jerome Ateudjieu, Blaise Genton, Beat Stoll, and Ayok Maureen Tembei
- Subjects
Pediatrics ,medicine.medical_specialty ,030231 tropical medicine ,Immunology ,Meningococcal Vaccines ,Neisseria meningitidis ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Immunology and Allergy ,030212 general & internal medicine ,Pharmacology ,Vaccines, Conjugate ,Immunization Programs ,business.industry ,Vaccination ,medicine.disease ,Clinical trial ,Safety profile ,Vaccination Campaigns ,Meningococcal conjugate vaccine ,business ,Meningitis ,MenAfriVac ,Research Paper - Abstract
The study aimed to assess the capacity of AEFI surveillance during vaccination campaigns with the new conjugate meningitis vaccine (MenAfrivac). A systematic review of studies on MenAfrivac™ published in English during 2001-2016 was done.AEFIs incidence (I) was estimated and compared between MenAfrivac™ clinical trials and immunization campaigns using incidence difference (Id). Nine studies were included with an overall local AEFI I of 11,496/100,000 doses administered per week in clinical trials and 0.72/100,000 doses in immunization campaigns. An Id of 11,497.92 [11,497.91-11,497.93] and 17,243.20 [17,241.80-17,245.90] per 100,000 doses administered per week for overall local and systemic AEFI, respectively, were observed with highest from clinical trials. The incidence of AEFIs after MenAfrivac™ vaccination was far lower in campaigns than in clinical trial studies. Current capacity of AEFI surveillance during vaccination campaigns requires extensive re-assessment of its structure and capacity.
- Published
- 2019
- Full Text
- View/download PDF